Overview

Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults

Status:
Recruiting

Trial end date:
2024-03-20

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety and tolerability of single dose of GB-6002 (Ropivacaine) Local Infiltration in healthy male Adults. And, It is to compare pharmacokinetic characteristics of GB-6002 single dose injection with active comparator.

Phase:

Phase 1

Details

Lead Sponsor:

G2GBio, Inc.

Treatments:

Ropivacaine